Regencell Bioscience (NASDAQ:RGC) Releases Quarterly Earnings Results

Regencell Bioscience (NASDAQ:RGC) announced its earnings results on Friday. The company reported $0.00 EPS for the quarter, FiscalAI reports.

Regencell Bioscience Price Performance

Shares of RGC stock traded down $2.19 on Friday, hitting $29.28. 94,823 shares of the company’s stock were exchanged, compared to its average volume of 331,924. Regencell Bioscience has a 12 month low of $6.13 and a 12 month high of $83.60. The company has a 50 day moving average of $27.18 and a 200 day moving average of $23.85.

Hedge Funds Weigh In On Regencell Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of RGC. Seven Fleet Capital Management LP purchased a new stake in Regencell Bioscience in the fourth quarter worth $92,000. Hudson Bay Capital Management LP bought a new stake in Regencell Bioscience during the fourth quarter valued at $275,000. Vident Advisory LLC boosted its stake in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares during the period. XTX Topco Ltd purchased a new position in shares of Regencell Bioscience in the third quarter worth about $598,000. Finally, BNP Paribas Financial Markets purchased a new position in Regencell Bioscience during the 2nd quarter valued at about $768,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Key Stories Impacting Regencell Bioscience

Here are the key news stories impacting Regencell Bioscience this week:

• Negative Sentiment: A class action was filed against Regencell and certain officers in the U.S. District Court for the District of Maryland alleging violations of Sections 10(b) and 20(a) and Rule 10b‑5 for the Oct. 28, 2024–Oct. 31, 2025 class period; this is the substantive litigation that is driving legal risk. Pomerantz files class action (PR Newswire)
• Negative Sentiment: Multiple nationally known securities firms (Glancy Prongay Wolke & Rotter; Schall Law Firm; Faruqi & Faruqi; Rosen; Bragar Eagel & Squire; Kaplan Fox; Gross; others) have issued investor alerts and are soliciting lead‑plaintiff candidates — amplifying media attention and selling pressure. Glancy Prongay Wolke & Rotter deadline alert (BusinessWire)
• Negative Sentiment: Law firms continue to remind investors of the June 23, 2026 lead‑plaintiff deadline and the opportunity to seek appointment — an administrative timeline that concentrates filings and investor outreach in the near term. Schall Law Firm investor notice (GlobeNewswire)

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.